Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study

PURPOSE: mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the association between treatment-associated immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Schettini, Francesco, Sobhani, Navid, Ianza, Anna, Triulzi, Tiziana, Molteni, Alfredo, Lazzari, Maria Chiara, Strina, Carla, Milani, Manuela, Corona, Silvia Paola, Sirico, Marianna, Bernocchi, Ottavia, Giudici, Fabiola, Cappelletti, Maria Rosaria, Ciruelos, Eva, Jerusalem, Guy, Loi, Sherine, Fox, Stephen B., Generali, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599144/
https://www.ncbi.nlm.nih.gov/pubmed/32770287
http://dx.doi.org/10.1007/s10549-020-05856-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599144/
https://www.ncbi.nlm.nih.gov/pubmed/32770287
http://dx.doi.org/10.1007/s10549-020-05856-3

Ejemplares similares